Loading patent…
AssigneeBoard of Regents, The University of Texas System
InventorsAndrew ELLINGTON, Elizabeth GARDNER, Jimmy GOLLIHAR, Joshua LUTGENS, Edward MARCOTTE, Colleen MULVIHILL
Estimating the term…
Disclosed herein is an engineered eukaryotic cell which expresses a heterologous G protein coupled receptor (GPCR), wherein native Ste2 and/or Ste3 have been replaced with a heterologous GPCR: and further wherein native G alpha protein (Gpa1) has been replaced with a gene encoding a chimeric Gpa1. The GPCR disclosed herein can be a cannabinoid receptor. such as human cannabinoid receptor type I (CB1R). Also disclosed are methods of making the engineered eukaryotic cell. and methods of using the engineered eukaryotic cell. Also encompassed by this invention are biosensors comprising CB1R and CB2R. and methods of using them.
A method of engineering a eukaryotic cell to express a heterologous G protein coupled receptor (GPCR), wherein said GPCR is a cannabinoid receptor, the method comprising:
5-6. (canceled)
(canceled)
19-20. (canceled)
An engineered eukaryotic cell which expresses a heterologous G protein coupled receptor (GPCR), wherein native Ste2 and/or Ste3 have been replaced with a heterologous GPCR, wherein said heterologous GPCR has a truncated N terminus of at least 5 residues;
22-39. (canceled)
A method of identifying a compound capable of binding to a non-naturally occurring GPCR, the method comprising:
42-71. (canceled)
A method of determining relative binding of a compound to CB1R and CB2R, the method comprising:
73-84. (canceled)
A biosensor for the detection of compounds which interact with CB1R, CB2R, or both, wherein the biosensor comprises both CB1R and CB2R.
86-90. (canceled)
Dependencies are inferred from the claim text.